Patents by Inventor Carolyn L. Ruby

Carolyn L. Ruby has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Process for producing immunosuppressant agent
    Patent number: 5324644
    Abstract: Described is a new process for producing the immunosuppressant, L-682,993, a C-31 demethylated derivative of L-679,934 (FK-506), produced under fermentation conditions utilizing the new mutant microorganism Streptomyces sp. (Merck Culture Collection MA 7017) ATCC No. 55334, being a blocked second generation mutant of Streptomyces sp. (MA 6858) ATCC No. 55098. The macrolide immunosuppressant is useful in preventing human host rejection of foreign organ transplants, e.g. bone marrow and heart transplants.
    Type: Grant
    Filed: July 28, 1992
    Date of Patent: June 28, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Carolyn L. Ruby, Christine C. Chung, Byron H. Arison
  • Process for producing immunosuppressant agent L-683942 by fermentation
    Patent number: 5272068
    Abstract: Described is a new process for producing the immunosuppressant, L-683,742, a C-31 demethylated, derivative of L-683,590 (FK-520), produced under fermentation conditions utilizing the new mutant microorganism, Streptomyces hygroscopicus subsp. ascomyceticus (Merck Culture Collection MA 6646) ATCC No. 53855, being a blocked mutant of Streptomyces hygroscopicus subsp. ascomyceticus (MA 6475) ATCC No. 14891. The macrolide immunosuppressant is useful in preventing human host rejection of foreign organ transplants, e.g. bone marrow and heart transplants.
    Type: Grant
    Filed: July 23, 1991
    Date of Patent: December 21, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Carolyn L. Ruby, Susan J. Danis, Byron H. Arison
  • Cloning genes from Streptomyces avermitilis for avermectin biosynthesis and the methods for their use
    Patent number: 5252474
    Abstract: There are disclosed plasmids containing DNA isolated from Streptomyces avermitilis, the microorganism which is used to prepare avermectin compounds, identified as pAT1, pVE650 pVE855, pVE859, pVE1446, pVE923, and pVE924 which contain the genetic information for the biosynthesis of the avermectins. Methods for the isolation of such plasmid and for the manipulation of the plasmids to alter the formation of the avermectin compound are also disclosed.
    Type: Grant
    Filed: March 14, 1990
    Date of Patent: October 12, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Keith M. Gewain, Douglas J. MacNeil, Tanya MacNeil, Philip S. Paress, Carolyn L. Ruby, Stanley L. Streicher